San Antonio, TX, September 25, 2015 --(PR.com
)-- Pryor Medical Devices (The REBOA CompanyTM), today announced it has closed a $5 million Series B preferred round to support the development of its flagship ER-REBOA™ Catheter for temporary occlusion of large vessels. While the company’s device has not been cleared for human use, it has been recently submitted to the FDA for regulatory approval.
“Pryor Medical Devices’ business model is very compelling. They are taking lessons discovered by military doctors at war, and using them to create business opportunities and save lives back home,” said Ray L. Hunt, executive chairman, Hunt Consolidated, LLC and Partner at BriarPatch. “We see Pryor Medical as a leader in the emerging field of developing minimally invasive endovascular solutions for trauma.”
“We have a world-class clinical and technical team working to save lives while creating compelling business opportunities,” said David Spencer, CEO of Pryor Medical Devices. “The ER-REBOA Catheter is a technology born as a lesson from war, which also addresses a large, inadequately met civilian need to temporarily occlude large blood vessels here at home.”
Based on lessons learned during war, there is strong clinical interest in using minimally invasive vascular techniques in cases of trauma. As an example, REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta) is the temporary occlusion of the largest blood vessel, the aorta. The team at Pryor Medical has an unlimited, exclusive, worldwide license to underlying intellectual property created by two of the world’s leading REBOA practitioners, which it has improved and expanded upon. While the company’s flagship device has not yet been cleared for human use, it has been submitted to the FDA for future regulatory approval.
About Pryor Medical Devices – The REBOA Company™
Pryor Medical Devices, Inc. (The REBOA CompanyTM) is an innovative medical device company that designs, develops and commercializes minimally invasive solutions for vascular trauma. Our flagship product is the ER-REBOATM Catheter, a 7 Fr compatible balloon catheter for temporary occlusion of large vessels. The ER-REBOATM Catheter has not yet been cleared for human use, although it has been submitted to the FDA for regulatory approval. More information can be found at www.pryormedical.com